Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline

BackgroundThe live attenuated 17DD Yellow Fever vaccine is one of the most successful prophylactic interventions for controlling disease expansion ever designed and utilized in larger scale. However, increase on worldwide vaccine demands and manufacturing restrictions urge for more detailed dose sparing studies. The establishment of complementary biomarkers in addition to PRNT and Viremia could support a secure decision-making regarding the use of 17DD YF vaccine subdoses. The present work aimed at comparing the serum chemokine and cytokine kinetics triggered by five subdoses of 17DD YF Vaccine.MethodsNeutralizing antibody titers, viremia, cytokines and chemokines were tested on blood samples obtained from eligible primary vaccinees.Results and discussionThe results demonstrated that a fifty-fold lower dose of 17DD-YF vaccine (587 IU) is able to trigger similar immunogenicity, as evidenced by significant titers of anti-YF PRNT. However, only subdoses as low as 3,013 IU elicit viremia kinetics with an early peak at five days after primary vaccination equivalent to the current dose (27,476 IU), while other subdoses show a distinct, lower in magnitude and later peak at day 6 post-vaccination. Although the subdose of 587 IU is able to trigger equivalent kinetics of IL-8/CXCL-8 and MCP-1/CCL-2, only the subdose of 3,013 IU is able to trigger similar kinetics of MIG/CXCL-9, pro-inflammatory (TNF, IFN-γ and IL-2) and modulatory cytokines (IL-5 and IL-10).ConclusionsThe analysis of serum biomarkers IFN-γ and IL-10, in association to PRNT and viremia, support the recommendation of use of a ten-fold lower subdose (3,013 IU) of 17DD-YF vaccine.

[1]  A. Teixeira-Carvalho,et al.  Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first‐time vaccination: is this the key to prevent severe adverse reactions following immunization? , 2007, Clinical and experimental immunology.

[2]  S Lopes Ode,et al.  Studies on yellow fever vaccine. III--Dose response in volunteers. , 1988, Journal of biological standardization.

[3]  B. Pulendran,et al.  Learning vaccinology from viral infections , 2011, The Journal of experimental medicine.

[4]  Bali Pulendran,et al.  Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology , 2009, Nature Reviews Immunology.

[5]  Ana Carolina Campi-Azevedo,et al.  Cytokine signatures of innate and adaptive immunity in 17DD yellow fever vaccinated children and its association with the level of neutralizing antibody. , 2011, The Journal of infectious diseases.

[6]  G. Chang,et al.  Development of Multiplex Real-Time Reverse Transcriptase PCR Assays for Detecting Eight Medically Important Flaviviruses in Mosquitoes , 2006, Journal of Clinical Microbiology.

[7]  C. Rice,et al.  The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD 8 T Cell Response 1 , 2009 .

[8]  N. Jonsson,et al.  Real-time polymerase chain reaction as a rapid and efficient alternative to estimation of picornavirus titers by tissue culture infectious dose 50% or plaque forming units. , 2009, Microbiology and immunology.

[9]  A. Teixeira-Carvalho,et al.  Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults. , 2011, Vaccine.

[10]  V. Barban,et al.  Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines. , 2008, Journal of virological methods.

[11]  Bali Pulendran,et al.  Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity , 2006, The Journal of experimental medicine.

[12]  R. Marchevsky,et al.  Production of yellow fever 17DD vaccine virus in primary culture of chicken embryo fibroblasts: yields, thermo and genetic stability, attenuation and immunogenicity. , 2005, Vaccine.

[13]  O. Tomori.  Yellow Fever: The Recurring Plague , 2004, Critical reviews in clinical laboratory sciences.

[14]  D. Gubler.  The global resurgence of arboviral diseases. , 1996, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[15]  L. Camacho.  Yellow fever and public health in Brazil. , 2008, Cadernos de saude publica.

[16]  Luiz Antonio Bastos Camacho,et al.  17DD and 17D-213/77 Yellow Fever Substrains Trigger a Balanced Cytokine Profile in Primary Vaccinated Children , 2012, PloS one.

[17]  Shuzhao Li,et al.  Vaccine Activation of the Nutrient Sensor GCN2 in Dendritic Cells Enhances Antigen Presentation , 2014, Science.

[18]  English Only.  Who Expert Committee on Biological Standardization. , 2004, World Health Organization technical report series.

[19]  C. Pannuti,et al.  Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine. , 1999, Vaccine.

[20]  A. Teixeira-Carvalho,et al.  Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon‐γ and interleukin‐10 and low frequency of tumour necrosis factor‐α+ monocytes are hallmarks of active human visceral Leishmaniasis due to Leishmania chagasi infection , 2006, Clinical and experimental immunology.

[21]  Pedro Fernando da Costa Vasconcelos.  Febre amarela Yellow fever , 2003 .

[22]  A. Prata.  Yellow fever. , 2000, Memorias do Instituto Oswaldo Cruz.